Full Press Release Details
CORONADO BIOSCIENCES RAISES $3,500,000
THROUGH THE PRIVATE PLACEMENT OF RESTRICTED COMMON STOCK
Shares were sold at the closing price on November 6, 2014
Participating in the transaction were DAK Capital and Officers
and Directors, Dr. Lindsay A. Rosenwald, Michael S. Weiss and Malcolm Hoenlein
Burlington, Mass., November 7, 2014 - Coronado
Biosciences, Inc. (CNDO) announced today that it raised $3,501,750 through the sale of restricted common stock. The shares were
priced at the closing price on November 6, 2014. Participating in the financing were DAK Capital, Dr. Lindsay A. Rosenwald, Chairman
and CEO of the Company, Michael S. Weiss, Executive Vice Chairman and Malcolm Hoenlein, Director.
About Coronado Biosciences
Coronado Biosciences is a biopharmaceutical company dedicated
to investing in, acquiring, developing and commercializing novel pharmaceutical products. The Company's portfolio currently
includes novel immunotherapy agents for the treatment of autoimmune diseases and cancer. As part of its growth strategy, the company
plans to leverage its biopharmaceutical business and drug development expertise to acquire rights to, or to finance, innovative
pharmaceutical and biotechnology products, technologies and/or companies, using a variety of approaches including licensing, partnerships,
joint ventures, direct financings and/or public and private spin-outs. For more information, visit www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our growth strategy and product development programs and any other
statements that are not historical facts. Forward-looking statements are based on management's current expectations and are
subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our
growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks
relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; our
dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition;
as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes
in events, conditions or circumstances on which any such statement is based, except as required by law.
Lucy Lu, MD, Executive Vice President & Chief Financial
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com